DESVENLAFAXINE

USDailyMed:Desvenlafaxine AU:B2 N06AX23(WHO) AU:S4(Prescription only)BR:Class C1(Other controlled substances)CA:℞-onlyUS:℞-only (RS)-4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol 93413-62-8Y 125017 7158 DB06700Y 111300Y NG99554ANW D07793Y CHEBI:83527N ChEMBL1118Y DTXSID40869118 Interactive image OC2(C(c1ccc(O)cc1)CN(C)C)CCCCC2 InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3YKey:KYYIDSXMWOZKMP-UHFFFAOYSA-NY Desvenlafaxine, sold under the brand namePristiqamong others, is a medication used to treatdepression.It is anantidepressantof theserotonin–norepinephrine reuptake inhibitor(SNRI) class and is taken by mouth.It is recommended that the need for further treatment be occasionally reassessed.Studies have shown similar effectiveness compared to its parent compoundvenlafaxine. Common side effects includedizziness,trouble sleeping, increased sweating, constipation, sleepiness,anxiety, andsexual problems.In some patients, sexual dysfunction may persist even after the drug is discontinued, a condition known aspost-SSRI sexual dysfunction; regulatory agencies including theEuropean Medicines AgencyandHealth Canadahave recommended that desvenlafaxine's product labeling warn of this risk.Serious side effects may includesuicidein those under the age of 25,serotonin syndrome, bleeding,mania, andhigh blood pressure. Desvenlafaxine was approved for medical use in the United States in 2008.In Europe its application for use was denied in 2009, although has since been approved for Spain and Germany.In 2023, it was the 189th most commonly prescribed medication in the United States, with more than 2million prescriptions.